GSK plc GSK announced that the European Commission has granted approval for the expanded use of Jemperli (dostarlimab) plus ...

The FDA has cleared GSK's PD-1 inhibitor Jemperli as a treatment for all adult patients with primary advanced or recurrent endometrial cancer, a key part of the company's growth ambitions for the ...

GSK said last week it plans to file for approval of Jemperli in this setting in the first half of 2023, and if it gets the nod from regulators, the drug could claim a category of the endometrial ...

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme to explore ...

GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant ...

GSK’s Jemperli is designed to help the body’s immune system find and attack cancer cells, and is already approved in the EU ...

GSK (GSK) announced the European Commission has approved Jemperli, or dostarlimab, in combination with chemotherapy for first-line treatment of ...

GSK plc (GSK, GSK.L) announced the European Commission has approved Jemperli in combination with chemotherapy for first-line ...

European regulators have expanded the usage of GSK's Jemperli drug for endometrial cancer, the pharmaceutical firm announced ...